Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
2024-512803-37-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 42
01
Overview
Phase 3, randomised, double-blind trial in progressive pulmonary fibrosis (PPF) comparing BI 1015550 with Placebo (2 arms). Primary endpoint: Absolute change from baseline in Forced Vital Capacity (FVC) [mL] at Week 52. Started Sep 2024; status: completed.
02
Drugs
nerandomilast
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on 2024-512803-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512803-37-00.